Please assess the completion status of the following clinical trial:

Trial Title: Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:~Acute onset (defined below) of:~1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio \< 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)~2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph~3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.~In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first meeting ARDS criteria per the Berlin definition of ARDS.~Exclusion Criteria:~1. Age less than 18 years~2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS~3. Pregnant or breast-feeding~4. Prisoner~5. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years~6. Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%~7. Moderate to severe liver failure (Childs-Pugh Score \> 12)~8. Severe chronic respiratory disease with a PaCO2 \> 50 mm Hg or the use of home oxygen~9. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).~10. Major trauma in the prior 5 days~11. Lung transplant patient~12. No consent/inability to obtain consent~13. Moribund patient not expected to survive 24 hours~14. WHO Class III or IV pulmonary hypertension~15. Documented deep venous thrombosis or pulmonary embolism within past 3 months~16. No arterial line/no intent to place an arterial line~17. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol~18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (Type: EXPERIMENTAL): A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).